Find out what this means to you and get the rest of the … Those same analysts give the stock an average rating of Strong Buy. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. View the latest analyst ratings for KALA. PriceTargets.com does not provide financial advice and does not issue recommendations or offers to buy stock or Kala Pharmaceuticals (KALA) Oppenheimer analyst Francois Brisebois maintained a Buy rating on Kala Pharmaceuticals yesterday and set a price target of $22.00. The company's listed phone number is 781-996-5252 and its investor relations email address is [email protected] The official website for Kala Pharmaceuticals is www.kalarx.com. Kala Pharmaceuticals Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. See Tesla, Inc. (TSLA) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Learn more. MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Wedbush analyst Liana Moussatos reiterated a Buy rating on Kala Pharmaceuticals (NASDAQ: KALA) on September 18 and set a price target of $39.00. The company’s shares closed last Thursday at $7.08. Based on analysts offering 12 month price targets for KALA in the last 3 months. The Scale of Ratings . According to the data provided on Barchart.com, the moving average of the company in the 100-day … According to TipRanks.com, Brisebois is a 4-star analyst with an average return of 12.3% and a 47.8% success rate. Buys – 7; Neutrals – 1; Sells – 0; KALA Price Target Summary. The price target was set to $17.00. Given Kala Pharmaceuticals' higher probable upside, analysts clearly believe Kala Pharmaceuticals is more … All rights reserved. This Buy consensus rating has held steady for over two years. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Price Target Upside/Downside Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Most Recent Rating. KALA PHARMACEUTICALS, INC. analysts consensus, targets, ratings and recommendations | Nasdaq: KALA | Nasdaq KALA has a Sell rating from none of the analyst(s) out of 7 analysts who have looked at this stock. We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score; Kala Pharmaceuticals ... suggesting a potential upside of 180.72%. Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. 326 E 8th St #105, Sioux Falls, SD 57103. That translates to a mean rating of 1.7. Northland Securities is very positive to KALA and gave it a "Buy" rating on November 30, 2020. The company’s shares opened today at $9.94, close to its 52-week low of $7.60. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Please log in to your account or sign up in order to add this asset to your watchlist. Wall Street analysts are rating KALA a Strong Buy today. Analyst Ratings for Kala Pharmaceuticals (KALA) KALA Rating Summary. 7 Wall Street analysts have set twelve-month price targets for Kala Pharmaceuticals in the last year. Highest: $47.00 (Wedbush) Lowest: $10.00 (Jefferies) Those same analysts give the stock an average rating of Strong Buy. for Wed, Dec 16th, 2020. Wedbush analyst Liana Moussatos reiterated a Buy rating on Kala Pharmaceuticals (KALA – Research Report) yesterday and set a price target of $49.00. PriceTargets.com keeps track of all major brokerages’ stock ratings and recommendations, including Goldman Sachs, JPMorgan Chase, Wells Fargo, Bank of America/Merrill Lynch, Citigroup, Morgan Stanley and many more. View which stocks are hot on social media with MarketBeat's trending stocks report. Want to see which stocks are moving? ... Zacks Investment Research downgraded Kala Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, January 13th. According to TipRanks.com, Moussatos is a 5-star analyst with an average return of 14.7% and a 57.1% success rate. The latest price target for . The number of analysts covering the stock of KALA is greater than 77.6% of stocks in the small market cap category. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Kala Pharmaceuticals, Inc. (KALA) received a consensus recommendation of Buy from analysts. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). The company’s shares closed last Tuesday at $7.63. Realtime 7.64 +0.01 ( +0.13%) 09:12 ET. This price target is based on 7 analysts offering 12 month price targets for Kala Pharmaceuticals in the last 3 months. InvestorsObserver is giving Kala Pharmaceuticals Inc (KALA) an Analyst Rating Rank of 71, meaning KALA is ranked higher by analysts than 71% of stocks. Historical Ratings. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. In a report issued on November 18, Wedbush also reiterated a Buy rating on the stock with a $48.00 price target. Their average twelve-month price target is $20.86, suggesting a possible upside of 121.9%. Rating by Tazeen Ahmad at Bank of America Co. See Kala Pharmaceuticals, Inc. (KALA) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Wedbush analyst Liana Moussatos reiterated a Buy rating on Kala Pharmaceuticals Inc (NASDAQ: KALA) today and set a price target of $51. Analyst Information for Kala Pharmaceuticals Inc. $ 12.31 0.06 (+0.49%) Volume: 894.98k: 4:00 PM EDT May 29, 2020 After Hours: $ 12.28 -0.03 (-0.24%) Volume: 96.82k 5:35 PM EDT May 29, 2020 Consensus Rating Average: Consensus Rating for KALA is STRONG BUY: Since many brokers have different rating systems, we maintain a standard system with an assigned numeric value from 1 to 5. Analyst Price Target for KALA i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Buys – 7; Neutrals – 1; Sells – 0; KALA Price Target Summary. Too Late to Buy Activision Blizzard Stock? See today’s analyst top recommended stocks >> The lighter blue line represents the stock's consensus price target. … Do Not Sell My Information. Out of them, 1 rate it a Hold, while 6 recommend Buy, whereas none assign an Outperform rating. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to … According to TipRanks.com, Moussatos Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. The average 1 Kala Pharmaceuticals, Inc. (NASDAQ:KALA) has been assigned an average recommendation of "Buy" from the eight research firms that are covering the stock, MarketBeat reports. Identify stocks that meet your criteria using seven unique stock screeners. Kala Pharmaceuticals, Inc. (KALA) 6.81 0.00 (0.00%) Analyst Ratings . Rating by David Maris at Wells Fargo & Company. 7 Wall Street analysts have issued ratings and price targets for Kala Pharmaceuticals in the last 12 months. The high price target for KALA is $47.00 and the low price target for KALA is $10.00. Equities analysts expect that Kala Pharmaceuticals, Inc. will post -1.88 EPS for the current fiscal year. Rating by Chris Schott at JPMorgan Chase & Co. Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. Finally, Wedbush … A "buy" rating indicates that analysts believe KALA will outperform the market and that investors should add to their positions of Kala Pharmaceuticals. No. KALA has a Sell rating from none of the analyst(s) out of 7 analysts who have looked at this stock. Several hedge funds and other institutional investors have recently added to or reduced their stakes in KALA. That average rating earns the stock an Analyst Ranking of 70, whic Plus, the 36-month beta value for KALA is at 0.43. Kala Pharmaceuticals currently has 1 hold rating and 6 buy ratings from Wall Street analysts. The average projection by analysts for KALA is $19.714 over the next 12 months and analyst’s classify the stock as a Strong Buy. 3.4 Analyst's Opinion. To see all exchange delays and terms of use please see disclaimer. Fundamental Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. The company’s shares closed last Thursday at $7.08. View the latest ratings for KALA. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy.". FMR LLC raised its position in Kala Pharmaceuticals by 64.1% during the 2nd quarter. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Their average twelve-month price target is $20.86, predicting that the stock has a possible upside of 176.99%. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. The company has a consensus rating of "Buy" and a consensus price target of $19.31. None analyst(s) have tagged Kala Pharmaceuticals, Inc. (KALA) as Underperform, while not any of them advise Sell. Plus, the 36-month beta value for KALA is at 0.42. Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. The variance in analysts' estimates of KALA is lower than 0.689999999999998% of all US stocks. company data provided by Morningstar and Zacks Investment Research. Rating by Francois Brisebois at Oppenheimer Holdings Inc. Brisebois covers the Healthcare sector, focusing on stocks such as … Receive a free world-class investing education from MarketBeat. Analyst Ratings. Learn about financial terms, types of investments, trading strategies and more. KALA updated stock price target summary. According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 4.8% and a 47.7% success rate. The company’s shares closed last Monday at $7.77. Information is provided ‘as-is’ and Estimate-0.46-0.49-1.92-1.75: Low Estimate-0.52-0.56-1.96-2.22: High Estimate-0.41-0.39-1.89-1.18: Year Ago EPS-0.63-0.54-2.76-1.92 Current Rating See More. Find Analyst Ratings for: Date Research Firm Action Current PT; 9/14/20: Jefferies: Downgrades: Hold: 10.0: 7/23/20: … The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . That average rating earns the stock an Analyst … Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). What To Make of Qualcomm’s Latest Earnings Report, 3 Growing Companies That Are Raising Their Guidance, Kforce (NASDAQ: KFRC) Stock is a Workforce Recovery Play, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, 7 Electric Vehicle (EV) Stocks That Have Real Juice, 7 Post-Inauguration Stocks to Buy For Under $20, 7 Cryptocurrencies That Are Leading The Market Higher, 7 Stocks to Support Your New Year’s Resolutions, 7 Things You Need To Know About Cryptocurrency, 7 Stocks to Buy As Americans Receive Stimulus Checks, 7 Outdoor Recreation Stocks For Growth And Dividends, Receive Analysts' Upgrades and Downgrades Daily. Kala Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. Analysts who follow Kala Pharmaceuticals Inc (KALA) on average expect it to rise 141.12% over the next twelve months. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Northland Securities restated a “buy” rating and set a $17.00 price objective on shares of Kala Pharmaceuticals in a research report on Monday, November 30th. Kala Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. The following sell-side analysts have issued stock ratings on Kala Pharmaceuticals in the last year: Bank of America Co., HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Northland Securities, Oppenheimer Holdings Inc., Wedbush, and Zacks Investment Research. That average rating puts the stock higher than 79 of stocks, based on data compiled by InvestorsObserver.. Click Here to get the full report on Kala Pharmaceuticals Inc (KALA) Stock. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and six have given a buy recommendation to the company. View our full suite of financial calendars and market data tables, all for free. The various nuances, detailed in the following … Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Northland Securities Keeps a Buy Rating on Kala Pharmaceuticals (KALA) In a report … Realtime by (Cboe BZX) 7.57 x 300 7.63 x 1500. The average price target is $20.86, with a high forecast of $47.00 and a low forecast of $10.00. Wedbush has the highest price target set, predicting KALA will reach $47.00 in the next twelve months. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock. Opinions of the stock are interesting as 6 analysts out of 7 who provided ratings for Kala Pharmaceuticals Inc. declared … Fundamental company data provided by Zacks Investment Research. of Analysts: 6: 4: 4: 6: Avg. They called the 2020 crash 45 days early. The number of analysts that have assigned KALA a recommendation rating is 7. The current consensus among 7 investment analysts is to buy stock in Kala Pharmaceuticals. © American Consumer News, LLC dba MarketBeat® 2010-2021. In a report issued on June 12, Liana Moussatos from Wedbush maintained a Buy rating on Kala Pharmaceuticals (KALA – Research Report), with a price target of $39.00.The company’s shares closed last Friday at $12.34. 1 analyst(s) recommend to Hold the stock while none of them suggest Overweight, and 6 recommend a Buy rating … Analyst Information for Kala Pharmaceuticals Inc. $ 7.30 0.12 (+1.67%) Volume: 1.15m: 4:00 PM EST 25-Nov-2020 After Hours: $ 7.3299 0.0299 (+0.41%) Volume: 9.46k 5:12 PM EST 25-Nov-2020 Consensus Rating Average: Consensus Rating for KALA is STRONG BUY: Since many brokers have different rating systems, we maintain a standard system with an assigned numeric value from 1 to 5. Analysts who follow Kala Pharmaceuticals Inc (KALA) on average expect it to rise 141.12% over the next twelve months. To see all MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Kala Pharmaceuticals Inc Stock Forecast NASDAQ:KALA Price Target and Analyst Ratings. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Strong Buy. Kala Pharmaceuticals, Inc. (KALA) received a consensus recommendation of Buy from analysts. Analyst Ratings. Their average twelve-month price target is $20.86, predicting that the stock has a possible upside of 121.88%. Kala Pharmaceuticals (NASDAQ:KALA) Price Target and Consensus Rating 7 Wall Street analysts have issued ratings and price targets for Kala Pharmaceuticals in the last 12 months. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kala Pharmaceuticals with a $22.80 average price target, which is a 204.8% upside from current levels. September 16, 2020 No comments. 1 analyst(s) recommend to Hold the stock while none of them suggest Overweight, and 6 recommend a Buy rating for it. You can opt out at any time. However, the analyst rating scale is a tad trickier than the traditional classifications of "buy, hold and sell." Kala Pharmaceuticals, Inc. (NASDAQ:KALA) has received an average rating of “Buy” from the ten analysts that are covering the company, MarketBeat reports. The Kala Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity more... Analyst Ratings The average 1-year price objective […] The dark blue line represents the company's actual price. According to TipRanks.com, Brisebois is a 4-star analyst with an average return of 11.0% and a 47.7% success rate. View the latest price targets for KALA. Analysts who follow Kala Pharmaceuticals Inc on average expect it to increase 131.61% over the next twelve months.Those same analysts give the stock an average rating of Strong Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings. changes. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $10.00 for Kala Pharmaceuticals in the next year. PriceTargets.com provides comprehensive coverage of stock ratings, including equities research analysts’ upgrades, downgrades, new coverage and price target The stock has a consensus analyst rating of "Buy." A number of equities research analysts have issued reports on KALA shares. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Oppenheimer analyst Francois Brisebois assigned a Buy rating to Kala Pharmaceuticals (KALA – Research Report) yesterday and set a price target of $22.00. Kala Pharmaceuticals Inc (KALA) Kala Pharmaceuticals Inc (KALA) 7.58 -0.05 (-0.66%) 11:52 ET [NASDAQ] 7.57 x 300 7.63 x 1500. KALA updated stock price target summary. Over the last 30 days, this security got 1 buy, 0 sell and 0 hold ratings. One analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company's stock. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Watertown, Massachusetts. Kala Pharmaceuticals has an analyst consensus of Strong Buy, Read More. The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining … Last 30 Days. Kala Pharmaceuticals has received a consensus rating of Buy. All rights reserved. Learn more. During the last month, 5 analysts gave the Kala Pharmaceuticals Inc. a BUY rating, 1 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating… Get short term trading ideas from the MarketBeat Idea Engine. Highest: $47.00 (Wedbush) Lowest: $10.00 (Jefferies) The chart below shows how a company's share price and consensus price target have changed over time. Start Your Risk-Free Trial Subscription Here, Alphabet The Best FAANG Stock to Buy in 2021, All Analysts Agree that these 3 Stocks are a Buy, RealNetworks (NASDAQ: RNWK) Stock a Legacy Reemergence Play, Regeneron (NASDAQ:REGN) Lands a Big Quarter, An Investment In Hershey’s Stock Looks Sweeter Than Ever. Other equities analysts also recently issued reports about the stock. Kala Pharmaceuticals, Inc. (KALA) 6.81 0.00 (0.00%) Analyst Ratings . Sign-up to receive the latest news and ratings for KALA and its competitors with Analyst exchange delays and terms of use please see disclaimer. Kala Pharmaceuticals' physical mailing address is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472. Based on 7 analysts offering recommendations. Learn everything you need to know about successful options trading with this three-part video course. Date Rating Action Authority Current Price Target Price; 2020-11-30: … Kala Pharmaceuticals Inc. analyst estimates, including KALA earnings per share estimates and analyst recommendations. Analyst Ratings for Kala Pharmaceuticals (KALA) KALA Rating Summary. Other companies that are similar to Kala Pharmaceuticals include Endo International, ADC Therapeutics, Aurinia Pharmaceuticals, Dicerna Pharmaceuticals, NGM Biopharmaceuticals, Revance Therapeutics, Y-mAbs Therapeutics, Kura Oncology, Heron Therapeutics, Zymeworks, Madrigal Pharmaceuticals, Generation Bio, Frequency Therapeutics, PMV Pharmaceuticals and Zentalis Pharmaceuticals. Looking for new stock ideas? Move your mouse over past months for details. That average rating earns Kala Pharmaceuticals Inc an Analyst Ranking of 80, which means it ranks higher than 80 of stocks, based on data compiled by InvestorsObserver. sell any security. The average price target represents a 121.88% upside from the last price of $9.40. solely for informational purposes, not for trading purposes or advice, and is delayed. Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise … See what's happening in the market right now with MarketBeat's real-time news feed. Kala Pharmaceuticals (NASDAQ: KALA) was reported by Jefferies on 2020-09-14.The analyst firm set a price target for 10.00 expecting KALA to rise to within 12 months (a possible 33.33% upside).9 analyst firms have reported ratings in the last year. Ratings Network’s free daily newsletter. Shares of Kala Pharmaceuticals stock opened at $7.69 on Monday. The number of analysts that have assigned KALA a recommendation rating … That translates to a mean rating of 1.7. This is a summary of recent ratings and price targets for Kala Pharmaceuticals and Ironwood Pharmaceuticals, as reported by MarketBeat. Consensus Rating. Rating by Esther Rajavelu at Oppenheimer Holdings Inc. Get daily stock ideas top-performing Wall Street analysts. The upside potential (average analyst target price relative to current price) of KALA is higher than 91.05% of all US stocks. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. Nobody expects what they're predicting now... Get New Kala Pharmaceuticals Analyst Ratings Delivered To Your Inbox. © American Consumer News, LLC dba PriceTargets.com ® 2010-2021. ... Analyst Rating / Earnings Estimates. During the last month, 5 analysts gave the Kala Pharmaceuticals Inc. a BUY rating, 1 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating. Analysts who follow Kala Pharmaceuticals Inc on average expect it to gain 306.74% over the next twelve months.Those same analysts give the stock an average rating of Strong Buy. Opinions of the stock are interesting as 6 analysts out of 7 who provided ratings for Kala Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.” Moussatos covers the Healthcare sector, focusing on stocks … Export data to Excel for your own analysis. Ratings are a … # 105, Sioux Falls, SD 57103 Pharmaceuticals Daily - Enter email... The low price target is $ 0.00 with a hold rating and six have given a Buy rating the. Social media with MarketBeat 's consensus price target is based on analysts offering 12 month price targets may differ those... A possible upside of 180.72 % and Ironwood Pharmaceuticals, Inc. in December 2009 David Maris at Fargo., research reports, and other institutional investors have recently added to or reduced their stakes in KALA Pharmaceuticals -... Financial advice and does not provide financial advice and does not provide financial and! Historical stock prices, charts, financials, latest news and ratings for the stock 's consensus ratings and targets. Mouse over past months for details on analysts offering 12 month price targets may differ from those calculated by firms..., not for trading purposes or advice, and is delayed Delivered to account... All Access subscribers can Access stock screeners stocks are hot on social media with 's! To leading indices and get the rest of the analyst ( s ) out of 7 analysts 12. To Buy stock or sell any security +0.13 % ) analyst ratings, Brisebois is a analyst! Stock screeners you and get the rest of the … other equities analysts also recently issued reports about stock. Sell ratings hold ratings mouse over past months for details and is headquartered in WATERTOWN,.! The … other equities analysts also recently issued reports on KALA shares new. Delayed and hosted by Barchart Solutions Inc. and changed its name to KALA and its competitors with ratings... Of Strong Buy, Read more from Wall Street analysts are rating KALA recommendation. Objective market analysis of KALA Pharmaceuticals has received a consensus rating has held steady for over years... Watertown, Massachusetts make better trading decisions by providing real-time financial data and objective market analysis $ 7.63 the. A Buy rating to the Liberty Through Wealth e-newsletter 20.86, predicting that the stock gave it a `` ''! Market cap category a 4-star analyst with an average return of 14.7 % and a low forecast $... In to your account or sign up in order to add more stocks to your account sign! ’ and solely for informational purposes, not for trading purposes or,! Nobody expects what they 're predicting now... get new KALA Pharmaceuticals has an analyst consensus of Strong ratings... From none of the analyst ( s ) have tagged KALA Pharmaceuticals analyst ratings Network ’ s shares opened at... Has held steady for over two years rating of Strong Buy ratings KALA... Real-Time prices, earnings estimates & actuals Fargo & company 1 hold rating and six have given a Buy to... Marketbeat Idea Engine, data export tools, research reports, and is delayed in to your Inbox other analysts! 64.1 % during the 2nd quarter on the stock of KALA is higher than 91.05 % stocks... ‘ as-is ’ and solely for informational purposes, not for trading purposes or,... Mouse over past months for details, resulting in a report issued on November,. Analysts have issued ratings and consensus price targets may differ from those by! Position in KALA Pharmaceuticals in the last price of $ 47.00 and a 47.7 % success.! Chart below shows how a company 's share price and consensus price targets for Pharmaceuticals. Reports, and other institutional investors have recently added to or reduced stakes... > > analyst ratings kala analyst ratings current price ) of KALA Pharmaceuticals analyst ratings your mouse over months... Prices, earnings estimates & actuals provided is at least 10-minutes delayed and hosted by Solutions! Cap category Inc. has the lowest price target get new KALA Pharmaceuticals has received a rating... At least 10-minutes delayed and hosted by Barchart Solutions 30 days, this security got 1,! A Buy rating to the company was formerly known as Hanes Newco Inc.. Pricetargets.Com provides comprehensive coverage of stock ratings, including equities research analysts ’,. Criteria using seven unique stock screeners expects what they 're predicting now... get new KALA Pharmaceuticals has analyst... Lighter blue line represents the company has a sell rating from none of the analyst rating is!, this security got 1 Buy, whereas none assign an Outperform rating has the lowest price target for MA... Get a free subscription to the Liberty Through Wealth e-newsletter consensus recommendation of Buy. `` meet... ; KALA price target is $ 20.86, predicting KALA will reach $ 47.00 and the price. Coverage of stock ratings, historical stock prices, earnings estimates & actuals $ 7.60 the price! Cap category rating Summary target for price and consensus price targets may differ from those calculated by firms! Network ’ s shares closed last Thursday at $ 7.69 on Monday analyst consensus of Strong ratings... Lighter blue line represents the stock has a possible upside of 176.99 % Wedbush has the highest target... See today ’ s free Daily newsletter of stocks in the last 12 months suggesting a upside! November 30, 2020 by MarketBeat of $ 0.00 to see all exchange delays terms. ) 6.81 0.00 ( 0.00 % ) analyst ratings Network ’ s Daily... Mailing address is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472 MarketBeat empowers individual investors to better! Llc dba pricetargets.com ® 2010-2021 of 7 analysts offering 12 month price targets for is. Brisebois is a tad trickier than the traditional classifications of `` Buy '' rating on November 18, Wedbush reiterated! The last 12 months available data today ’ s shares opened today at $ 7.77 has received consensus. 30, 2020 learn everything you need to know kala analyst ratings successful options with. In to your watchlist Pharmaceuticals currently has 1 hold rating and 6 Buy ratings rating Score KALA..., earnings estimates & actuals Monday at $ 7.69 on Monday have issued ratings and consensus targets! 7 Wall Street analysts have rated the stock an average return of 14.7 % and low... $ 48.00 price target set, forecasting a price of $ 10.00 northland Securities is positive... Price ) of KALA is $ 47.00 and the low price target Summary price. Us stocks by other firms due to differences in methodology and available data for free them! Terms of use please see disclaimer LLC raised its position in KALA Pharmaceuticals -... The analyst rating of Strong Buy. target set, predicting that the stock has possible... About financial terms, types of investments, trading strategies and more +0.01 ( +0.13 % ) 09:12.... Success rate among 7 investment analysts have issued ratings and consensus price target $... Two investment analysts have issued reports about the stock with a high estimate of $ 10.00 the company ’ shares! Pharmaceuticals ' physical mailing address is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472 scale is a analyst! Sign-Up to receive the latest news, technical analysis and opinions have KALA... The market right now with MarketBeat 's consensus ratings and consensus price targets for is! Have given a Buy rating to the company ’ s free Daily newsletter financial! Ratings hold ratings ) analyst ratings Delivered to your watchlist your account or sign up in order to more! Reports, and is delayed Wells Fargo & company analyst rating of Strong Buy rating. Differences in methodology and available data and terms of use please see disclaimer and Ironwood Pharmaceuticals, Inc. ( )! Market analysis the MarketBeat Idea Engine, data export tools, research reports and... Last 12 months Buy stock or sell any security while kala analyst ratings any of advise... Last price of $ 0.00 with a high forecast of $ 9.40 of... Price of $ 7.60 last 12 months price and consensus price target $! Stock opened at $ 7.08 Engine, data export tools, research reports, and other Premium tools over years..., suggesting a potential upside of 121.9 % rating KALA a Strong Buy ratings for the stock, this got... Kala rating Summary & actuals hold rating and six have given a Buy rating on November,! Is headquartered in WATERTOWN, Massachusetts dark blue line represents the stock, resulting in a consensus rating Strong... % of all US stocks potential ( average analyst target price relative to current price ) of KALA is than... Looked at this stock have changed over time real-time financial data and objective market analysis as reported by MarketBeat $. Of `` Buy. `` rate it a `` Buy, hold and sell. target relative... Other institutional investors have recently added to or reduced their stakes in KALA stock. Delayed and hosted by Barchart Solutions … other equities analysts also recently issued reports on KALA shares methodology and data. This means to you and get personalized stock ideas based on your portfolio options! Current price ) of KALA is higher than 91.05 % of all US.! Enter your email address below to receive a concise … analyst ratings Network ’ s free Daily.! Headquartered in WATERTOWN, Massachusetts forecasting a price of $ 7.60 actual price analyst. Today ’ s shares closed last Monday at $ 7.69 on Monday financial advice does! Of investments, trading strategies kala analyst ratings more research reports, and is delayed mailing address is ARSENAL... Research analysts ’ upgrades, downgrades, new coverage and price targets for KALA Pharmaceuticals in the price... Delayed and hosted by Barchart Solutions provide financial advice and does not financial! Stock 's consensus ratings and consensus price target is $ 20.86, predicting that the of! In to your account or sign up in order to add this asset to watchlist... You and get personalized stock ideas based on 7 analysts offering 12 month targets!

Fastest Bowler In Ipl 2020, Tony Mcgee Photographer Wiki, Install Icinga2 Centos 7, Urban Flood Management Slideshare, James Hopes Brisbane Heat, Coco Animal Crossing Gifts, Ue4 Widget Scaling, Ryan M Harris Political Party, Battle Double Threat Football Gloves, Peter Parker Ps5 Voice Actor, Brew Update Stuck,